

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Express Mail # EM 490 494 254 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: WANG et al.

Serial No.: 08/552,839

Group Art Unit: 1636

Filed: November 3, 1995

Examiner: D. Guzo

For: NOVEL ADENOVIRAL VECTORS, Atty Docket No.: 7639-044
 PACKAGING CELL LINES,
 RECOMBINANT ADENOVIRUSES,
 AND METHODS

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

The above-identified patent application is a continuation-in-part of U.S. Application No. 08/333,680 filed November 3, 1994. References AA to BM listed in the attached revised form PTO 1449 was made of record in the parent application. Thus, pursuant to 37 C.F.R. § 1.98(d), and so not to overly burden the Examiner, Applicants are not supplying copies of the references cited in the revised form

NY2 - 911.1.1

12/15/1998 RUC:AT 00000005 161150 08552839
 01 FC:126 240.00 CH

#12
 12/31/98

DEC 10 1998

PTO 1449 at this time. However, if the Examiner would prefer, copies of the identified references will be made available upon request. A copy of the reference listed as BN is submitted with this statement.

Identification of the listed reference is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as prior art against the application. Consequently, Applicants respectfully decline to use PTO-1449, since this form identifies all of the references cited therein as "Prior Art". As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited".

Pursuant to 37 C.F.R. §1.97(c), it is estimated that a fee of \$240.00 is due. Please charge the required fee to Pennie & Edmonds LLP Deposit Account 16-1150.


Applicants respectfully request that the Examiner review the foregoing references and that the references be made in the file history of the application.

Respectfully submitted,

Date: December 10, 1998

Laura A. Coruzzi by: *Jacqueline Benn*
 Laura A. Coruzzi (Reg. No.) 30,742 Reg No. 43,492

PENNIE & EDMONDS LLP
 1155 Avenue of the Americas
 New York, New York 10036-2711
 (212) 790-9090



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

7639-044

APPLICATION NO.

08/552,839

APPLICANT

WANG et al.

FILING DATE

November 3, 1995

GROUP

1636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/D.G./	BM	5,670,488	9/23/97	Gregory			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/D.G./	AA	WO 93/19191	9/93	PCT				X
↓	AB	WO 94/08026	4/94	PCT				
	AC	WO 95/02697	1/95	PCT				X
	AD	WO 94/28152	12/94	PCT			X	
	AE	WO 94/12649	6/94	PCT				
	AR	WO 96/18418	6/96	PCT			X	
	AS	WO 95/34671	12/95	PCT			X	
	AT	WO 95/02697	1/95	PCT			X	
	AU	WO 94/28152	12/94	PCT			X	
	AV	WO 95/27071	10/95	PCT			X	
	AW	WO 94/28938	12/94	PCT			X	
/D.G./	AX	WO 94/23582	10/94	PCT			X	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/D.G./	AF	Imler et al., "Second generation adenoviral and retroviral vectors for gene therapy of inherited and acquired diseases", Abstract submitted at 1994 Meeting on Gene Therapy, September 21-25, 1994.
/D.G./	AG	Vincent et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene", <u>Nature Genetics</u> 5:130-134 (1993)
/D.G./	AH	Quantin et al., "Adenovirus as an expression vector in muscle cells <i>in vivo</i> ", <u>Proc. Natl. Acad. Sci. U.S.A.</u> 89:2581-2584 (1992)
/D.G./	AI	Ragot et al., "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of <i>mdx</i> mice", <u>Letters to Nature</u> 361:647-650 (1993)
/D.G./	AJ	Li et al., "Assessment of recombinant adenoviral vectors for hepatic gene therapy", <u>Human Gene Therapy</u> 4:403-409 (1993)
/D.G./	AK	Engelhardt et al., "Ablation of <i>E2A</i> in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver", <u>Proc. Natl. Acad. Sci. USA</u> 91:6196-6200 (1994)

/D.G./	AL	Yang et al., "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy", <u>Proc. Natl. Acad. Sci. USA</u> 91 :4407-4411 (1994)
/D.G./		Brody et al., "Adenovirus-mediated <i>in vivo</i> gene transfer", <u>Annals New York Academy of Sciences</u> 716 :90-103 (1994)
/D.G./		Berkner et al., "Generation of adenovirus by transfection of plasmids", <u>Nucleic Acids Research</u> 11 (17):6003-6021 (1983)
/D.G./	AO	Gwo, et al., "Characterization of mouse inhibin α gene and its promoter", <u>Biochemical and Biophysical Res. Communications</u> 186 (1):293-300 (1992)
/D.G./	AP	Bridge et al., "Interaction of adenoviral E4 and E1b products in late gene expression", <u>Virology</u> 174 :345-353 (1990)
/D.G./	AQ	Borrelli et al., "Signal transduction and gene control: the cAMP pathway", <u>Critical Reviews in Oncogenesis</u> 3 (4):321-338 (1992)
/D.G./	AY	Klessig et al., "Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell", <u>Molecular and Cellular Biology</u> 4 (7):1354-1362 (1984)
/D.G./	AZ	Weinberg et al., "A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus Type 2", <u>Proc. Natl. Acad. Sci. USA</u> 80 :5383-5386 (1983)
/D.G./	BA	Pei et al., "Regulation of the alpha inhibin gene by cyclic adenosine 3',5'-monophosphate after transfection into rat", <u>Mol. Endocrinol.</u> 5 (4):521-534 (1991)
/D.G./	BB	Armentano et al., "Second generation adenovirus vectors for cystic fibrosis gene therapy", <u>J. Cell. Biochem.</u> 18 :222. (1994)
/D.G./	BC	Gossen and Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters", <u>Proc. Natl. Acad. Sci. USA</u> 89 :5547-5551 (1992)
/D.G./	BD	Ketner et al., "Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids", <u>Nucl. Acids. Res.</u> 17 :3037-3049 (1989)
/D.G./	BE	Fallaux et al., "Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors", <u>Human Gene Therapy</u> 7 :215-222 (1996)
/D.G./	BF	Wang and Finer, "A packaging cell line for propagation of recombinant adenovirus containing two lethal gene-region deletions", <u>Gene Ther.</u> 2 :775-783 (1995)
/D.G./	BG	Krougliak and Graham, "Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants", <u>Human Gene Ther.</u> 6 :1575-1586 (1995)
/D.G./	BH	Weiden and Ginsburg, "Deletion of the E4 region of the genome produces adenovirus DNA concatemers", <u>Proc. Natl. Acad. Sci. USA</u> 91 :153-157 (1994)
/D.G./	BI	Feng et al., "Analysis of the 5'-flanking regions of rat inhibin α - and β -B-subunit genes suggests two different regulatory mechanisms", <u>Mol. Endo.</u> 3 :1914-1925 (1989)

/D.G./ 3219	BJ	Scaria et al., "Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes", <u>Gene Ther.</u> 2:295-298 (1995)
/D.G./ 3219	BK	Goldsmith et al., "Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells", <u>Human Gene Ther.</u> 5:1341-1348 (1994)
/D.G./ 3219	BL	Falgout and Ketner, "Adenovirus early region 4 is required for efficient virus particle assembly", <u>J. Virol.</u> 61:3759-3768 (1987)
/D.G./	BN	Horowitz, "Adenoviridae and Their Replication", <u>Fundamental Virology</u> , Second Edition, edited by B. N. Fields, D. M. Knipe et al., Raven Press, Ltd., N.Y. (1991)
EXAMINER /David Guzo/		DATE CONSIDERED 01/02/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through in conformance and not considered. Include copy of this form with next communication to applicant.		